TELO Telomir Pharmaceuticals, Inc.: Rasio nilai perusahaan marang pendapatan

Logo perusahaan publik Telomir Pharmaceuticals, Inc. (TELO)

Exclusive anti-aging patents and stringent FDA oversight create significant barriers to entry for Telomir Pharmaceuticals (TELO). This price-to-sales ratio chart visualizes these market positions, where the 0.00 mark serves as the current metric. The absence of commercial products eliminates cash flow predictability, while operating expenses are fully covered by burning through existing reserves.

Telomir Pharmaceuticals (TELO): Rasio nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

TELO (Telomir Pharma): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:
- informasi babagan dhuwit lan arus kas:
Pambiji fundamental:telomirpharma.com TELO
Produk asli Telomir Pharmaceuticals Inc

For Telomir Pharmaceuticals (TELO), which is developing innovative telomere restoration methods in gerontology, assessing the business value excluding debt load is critically important. This multiple compares the total enterprise value with the volume of generated sales, allowing for the determination of the real price of every dollar of revenue. By analyzing changes in the EV/Sales multiple, an investor can identify asset undervaluation or systemic risks of the company relative to US industry standards.

Analisis pesaing

HLN: Rasio nilai perusahaan marang pendapatan|Kenvue Corp (KVUE) - Rasio nilai perusahaan marang pendapatan|Verona Pharma PLC - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Jyong Biotech Ltd|Multiplikator EV/Sales Ligand Corp|Multiplikator EV/Sales AMRX|Rasio total nilai perusahaan marang pendapatan Perrigo Company plc|Multiplikator EV/Sales ALVO (Alvotech Biopharmaceuticals)|LQDA: Rasio nilai perusahaan marang pendapatan|Galapagos N.V. - Multiplikator EV/Sales|ANIP - Multiplikator EV/Sales|MNKD: Multiplikator EV/Sales|amphastar.com (AMPH) - Multiplikator EV/Sales|PCRX (Pacira Pharmaceuticals) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan ARS Pharmaceuticals, Inc. (SPRY)|Multiplikator EV/Sales TBPH|AQST (Aquestive Therapeutics) - Nilai bisnis marang pendapatan|scPharmaceuticals, Inc. - Nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan TECX|tonixpharma.com - Multiplikator EV/Sales|Nilai bisnis marang pendapatan SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Rasio nilai perusahaan marang pendapatan|Nilai perusahaan marang pendapatan BioHarvest|Nilai perusahaan marang pendapatan EXOZ|Nilai perusahaan marang pendapatan Oramed Pharmaceuticals (ORMP)|Nilai perusahaan marang pendapatan ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Rasio nilai perusahaan marang pendapatan|Multiplikator EV/Sales ABVC (ABVC BioPharma Inc)|CPIX - Nilai perusahaan marang pendapatan|Quantum BioPharma Corp - Multiplikator EV/Sales|FGEN (fibrogen.com) - Rasio nilai perusahaan marang pendapatan|Rani Therapeutics Inc (RANI) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan SNYR|Rasio nilai perusahaan marang pendapatan Rallybio Corp|Rasio nilai perusahaan marang pendapatan LEXX|Multiplikator EV/Sales PULM|PTHL: Nilai perusahaan marang volume dodolan|Multiplikator EV/Sales APM (Aptorum Group Ltd)|LYRA - Nilai perusahaan marang pendapatan|Impact BioMedical Inc - Multiplikator EV/Sales|Nilai perusahaan marang volume dodolan TNFA|YCBD (cbdmd.com) - Nilai perusahaan marang pendapatan|painreform.com - Nilai bisnis marang pendapatan|Nilai perusahaan marang pendapatan CYTO|Rasio nilai perusahaan marang pendapatan LIPO|Rasio nilai perusahaan marang pendapatan optinose.com (OPTN)|PIRS (Pieris Pharma) - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Procaps Group S.A. PROC|Rasio total nilai perusahaan marang pendapatan petrospharma.com (PTPI)|QLI - Rasio nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Rasio nilai perusahaan marang pendapatan